Bernard, PS, Wittwer, CT. (2002). Real-Time PCR technology for cancer diagnostics. Clin Chem, 48(8):1178-1185.
Capelle, LG, Van Grieken, NC, Lingsma, HF, Steyerberg, EW, Klokman, WJ, Bruno, MJ, Vasen, HF, Kuipers, EJ. (2010). Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology. 138:487–92. [PubMed: 19900449].
Coskun, T, Bina, HA, Schneider, MA, Dunbar, JD, Hu, CC, Chen, Y, Moller, DE, Kharitonenkov, A. (2008). Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 149:6018–6027.
Fukumoto, S (2008). Actions and mode of actions of FGF19 subfamily members. Endocr J, 55:23–31.
Fu, L, John, LM, Adams, SH, Yu, XX, Tomlinson, E, Renz, M, Williams, PM, Soriano, R, Corpuz, R, Moffat, B, Vandlen, R, Simmons, L, Foster, J, Stephan, JP, Tsai, SP, Stewart, TA. (2004). Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptindeficient diabetes. Endocrinology 145: 2594–2603.
Globocan. 2012. at http://globocan.iarc.fr/Default.aspx
Inagaki, T, Dutchak, P, Zhao, G, Ding, X, Gautron, L, Parameswara, V, Li, Y, Goetz, R, Mohammadi, M, Esser, V, Elmquist, JK, Gerard, RD, Burgess, SC, Hammer, RE, Mangelsdorf, DJ, Kliewer, SA. (2007). Endocrine Regulation of the Fasting Response by PPARalpha-Mediated Induction of Fibroblast Growth Factor 21. Cell Metab, 5:415–425.
Jones, S. (2008) Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 5:42–48.
Kharitonenkov, A, Larsen, P. (2011) FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab. 22:81–86.
Kuipers, EJ, Rösch, T, Bretthauer, M. (2013). Colorectal cancer screening--optimizing current strategies and new directions. Nat Rev Clin Oncol. 10:130–42. Review of current state of art of colorectal cancer screening. [PubMed: 23381005].
Li, X, Ge, H, Weiszmann, J, Hecht, R, Li, YS, Véniant ,MM, Xu, J, Wu, X, Lindberg, R, Li, Y. (2009). Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS Lett. 583:3230–3234.
Rohani-Rasaf, M, Abdollahi, M, Jazayeri, S, Kalantari, N, Asadi-Lari, M. (2013). Correlation of cancer incidence with diet, smoking and socio- economic position across 22 districts of Tehran in 2008. Asian Pac J Cancer Prev. 2013; 14:1669–76. [PubMed: 23679254].
Salehi Nodeh, A, Ghafouri, S, Razavi, S, Mirshafie, SA. (2008). Assessment of TPS tumor marker with ELISA for early detection and monitoring of Breast cancer. Payavard Salamat; 2:84-88.
Tomlinson, E, Fu, L, John, L, Hultgren, B, Huang, X, Renz, M, Stephan, JP, Tsai, SP, Powell-Braxton, L, French, D, Stewart, TA. (2002). Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology. 143:1741–1747.
Vasen, HFA, Tomlinson, I, Castells, A. (2015).Clinical management of hereditary colorectal cancer syndromes. Nat Rev Gastroenterol Hepatol. 12:88–97. [PubMed: 25582351].
Warthin, AS. (1913). Heredity with reference to carcinoma: as shown by the study of the cases examined in the pathological laboratory of the University of Michigan. Arch Intern Med. 12:546–55.
Wu, X, Ge, H, Lemon, B, Weiszmann, J, Gupte, J, Hawkins, N, Li, X, Tang, J, Lindberg, R, Li, Y. (2009). Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci U S A. 106:14379–14384.
Xu, J, Lloyd, DJ, Hale, C, Stanislaus, S, Chen, M, Sivits, G, Vonderfecht, S, Hecht, R, Li, YS, Lindberg, RA, Chen, JL, Jung, DY, Zhang, Z, Ko, HJ, Kim, JK, Véniant, MM. (2009). Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 58:250–259.
Xu, J, Stanislaus, S, Chinookoswong, N, Lau, YY, Hager, T, Patel, J, Ge, H, Weiszmann, J, Lu, SC, Graham, M, Busby, J, Hecht, R, Li, YS, Li, Y, Lindberg, R, Véniant, MM. (2009). Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin resistant mouse models—Association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 297: 1105–1114.